Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lung Diseases 2 Lung Neoplasms 1 Carcinoma 1

Interventions

Specimen Handling 7 Magnetic Resonance Spectroscopy 7 Cisplatin 6 pembrolizumab 4 durvalumab 4 Platinum 4 Carboplatin 4 1,2-diaminocyclohexaneplatinum II citrate 4 cemiplimab 3 Radiation 3 Paclitaxel 3 Cetuximab 3 Biopsy 3 (225)Ac-DOTA-c(RGDyK) 3 cabozantinib 2 atezolizumab 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Pemetrexed 2 Nivolumab 2 Immunoglobulin G 2 Docetaxel 2 Disulfides 2 ALT-803 2 130-nm albumin-bound paclitaxel 2 zipalertinib 1 repotrectinib 1 poly ICLC 1 ipatasertib 1 fludarabine phosphate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × zipalertinib × 30 days × Clear all

NCT05967689 2026-05-28

REZILIENT2

Taiho Oncology, Inc.

Phase 2 Recruiting

Carcinoma, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡